Sponsored

Regulatory stability, an abundance of dry powder and a strong pipeline of assets make medtech a compelling place to put capital to work, says DC Advisory’s Manish Gupta.

The IPO market is now open for quality tech stocks, and increased M&A activity will likely soon follow, say Adams Street Partners’ Brijesh Jeevarathnam and Robin Murray.

Large take-privates and carve-outs are on the menu as PE firms seek opportunities to unlock and drive value, says Baker McKenzie’s Eric Schwartzman.

Tech companies are well placed to answer PE sponsors’ growing questions about AI readiness, helping to buoy appetite for the sector, say KPMG’s Anuj Bahal, Patrick Carpenter and Greg Sward.

Darren Cohen of Goldman Sachs discusses the recalibration occurring in the technology market and how digital innovation is driving change across industries.

Spiraling pharmacy costs are creating a value creation opportunity for PE firms that are able to curb spending, says RX Benefits business development executive Will Statham.

Outdated assumptions about risk have held investors back from seizing impact opportunities, says Finance in Motion’s CEO Sylvia Wisniwski.

Three industry veterans talk about dealmaking, slow exits, tariffs and what lies ahead in the coming months.

There is now proof of concept that institutional and retail products can successfully be managed side by side, say Davis Polk’s Andrew Ahern, Oran Ebel, Christopher Healey and Leor Landa.